Press release
Global Xeljanz Tofacitnib Drug Market, Size, Share, Analysis Report & Forecast to 2026
The global xeljanz tofacitnib market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor for the growth of the market is the increase in the number of arthritis patients which include patients suffering from rheumatoid arthritis, psoriatic arthritis, and ulcerative arthritis. According to the Global RA Network, around 350 million people across the globe are suffering from arthritis. Arthritis caused the US healthcare system to spend around $303 billion each year, according to the data submitted by the Centers for Disease Control and Prevention (CDC). This, in turn, is driving the demand for xeljanz tofacitnib drugs for the treatment of arthritis patients.Free Sample Copy @ https://www.omrglobal.com/request-sample/xeljanz-tofacitnib-drug-market
The drug is marketed under the name of Xeljanz by Pfizer; it is a Janus kinases drug. The drug targets the reduction of inflammation caused by rheumatoid arthritis, by inhibiting the janus kinases which is involved in the inflammatory response pathway. In August 2021, the European Commission (EC) had approved the drug for the treatment of arthritis in Europe, which will further increase the demand for these drugs.
A Full Report of Global Xeljanz Tofacitnib Drug Market is Available at:
https://www.omrglobal.com/industry-reports/xeljanz-tofacitnib-drug-market
In addition to this, the EC has also approved the prolonged-release 11 mg version of the drug for the treatment of patients suffering from JPsA (juvenile psoriatic arthritis). In August 2021, Zydus Cadila, which is a part of Cadila Healthcare, received the final approval for the 180- days exclusivity for Xeljianz generic in the US.
Global Xeljanz Tofacitnib Drug Market – Segmentation
By Type
Tablets
Extended-Release Tablets
By Application
Rheumatoid Arthritis
Psoriatic Arthritis
Other
Global Xeljanz Tofacitnib Drug Market – Segmentation by Region
North America
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of the World
Company Profiles
Novartis Inc.
Eli Lilly
Pfizer Inc.
AbbVie
Zydus Cadila
Teva Pharmaceuticals
Cipla
Natco Pharma
Intas Biopharmaceuticals
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/xeljanz-tofacitnib-drug-market
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Xeljanz Tofacitnib Drug Market, Size, Share, Analysis Report & Forecast to 2026 here
News-ID: 2420936 • Views: …
More Releases from Orion Market Research
Eggshell Membrane Market Set to Witness Significant Growth by 2033 | Eggnovation …
The global Eggshell Membrane Market was valued at approximately USD 173.78 million in 2024, and is projected to reach USD 396.55 million by 2033, growing at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2033.
Eggshell Membrane Market Overview
The Eggshell Membrane Market is experiencing significant growth, driven by increasing consumer awareness of its health benefits, particularly in joint health and skin care. This natural biopolymer, rich in proteins…
Printable Solar Cells Market Set to Witness Significant Growth by 2033 | Armor G …
The global Printable Solar Cells Market was valued at approximately USD 1.2 billion in 2024, and is projected to reach USD 4.8 billion by 2033, exhibiting a strong compound annual growth rate (CAGR) of 16.7% from 2025 to 2033.
Printable Solar Cells Market Overview
The Printable Solar Cells Market is on a rapid upward trajectory, led by rising demand for flexible, lightweight, and cost-effective energy solutions. Printable photovoltaic technologies-including organic, perovskite,…
Sales Enablement Software Market Size Analysis, Competitive Insights, Leading Pl …
The Sales Enablement Software Market was valued at approximately USD 3.4 billion in 2024 and is projected to reach around USD 13.1 billion by 2033, growing at a compound annual growth rate (CAGR) of 14.7% from 2025 to 2033.
Sales Enablement Software Market Overview
The Sales Enablement Software Market is experiencing significant growth, driven by the increasing need for businesses to enhance their sales processes and improve team performance. These platforms…
Feed management software Market Set to Witness Significant Growth by 2033 | Prai …
The global Feed Management Software Market was estimated to be around USD 0.6 billion in 2024, and is projected to reach approximately USD 1.2 billion by 2033, growing at a compound annual growth rate (CAGR) of about 7.5% from 2025 to 2033.
Feed Management Software Market Overview
The Feed Management Software Market is expanding steadily as the agriculture and livestock industries shift toward digital transformation to optimize feed formulation and reduce…
More Releases for Xeljanz
Xeljanz Tofacitnib Drug Market By Application Analysis, Regional Outlook, Compet …
The global tofacitinib (Xeljanz) market is projected to experience significant growth over the coming years. In 2024, the market is estimated to be valued at approximately USD 3.12 billion. Looking ahead, forecasts suggest that the market could reach around USD 6.5 billion by 2032, reflecting a compound annual growth rate (CAGR) of approximately 8.69% during the period from 2025 to 2033.
Request a sample copy of this report at: https://www.omrglobal.com/request-sample/xeljanz-tofacitnib-drug-market
Xeljanz Tofacitnib…
Global Xeljanz Tofacitnib Drug Market Estimated to Experience a Hike in Growth b …
In 2023, the global Xeljanz (tofacitinib) market was valued at approximately USD 2.4 billion. It is projected to reach around USD 3.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2032.
Global Xeljanz Tofacitnib Drug Market Overview
The global Xeljanz (tofacitinib) drug market is driven by the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Xeljanz,…
XELJANZ Poised for Remarkable Market Expansion of Ulcerative Colitis by 2032
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on XELJANZ (Pfizer) providing insights into the drug market landscape and market forecast of XELJANZ upto 2032. The report, titled "XELJANZ Market Market Size, Forecast, and Drug Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of XELJANZ in 2032? XELJANZ Market…
Xeljanz (tofacitnib) Drug Consumption Market Overview with Detailed Analysis, Co …
New Jersey, United States - The Global Xeljanz (tofacitnib) Drug Consumption Marlet is comprehensively and accurately detailed in the report, taking into consideration various factors such as competition, regional growth, segmentation, and market size by value and volume. This is an excellent research study specially compiled to provide the latest insights into critical aspects of Global Xeljanz (tofacitnib) Drug Consumption. The report includes different market forecasts related to market size,…
Xeljanz (tofacitnib) Drug Market Top Companies Analysis, Regional Growth Overvie …
LOS ANGELES, United States: QY Research offers an encyclopedic study of the global Xeljanz (tofacitnib) Drug market with holistic insights into vital factors and aspects that impact future market growth. The global Xeljanz (tofacitnib) Drug market has been analyzed for the forecast period 2022-2028 and historical period 2017-2021. In order to help players to gain comprehensive understanding of the global Xeljanz (tofacitnib) Drug market and its critical dynamics, the research study…
Lawsuit filed for Investors in shares of AbbVie Inc. (NYSE: ABBV)
An investor, who purchased shares of AbbVie Inc. (NYSE: ABBV), filed a lawsuit over alleged violations of Federal Securities Laws by AbbVie Inc.
Investors who purchased shares of AbbVie Inc. (NYSE: ABBV) have certain options and for certain investors are short and strict deadlines running. Deadline: JUNE 6, 2022. NYSE: ABBV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Rinvoq is an anti-inflammatory drug manufactured by…
